Research Article
Year 2020,
Volume: 9 , 18 - 22, 29.06.2020
Abstract
References
- 1- İlknur KOZANOĞLU, Yusuf BARAN. The Use of Molecular Diagnostic Methods in Hematology Laboratory. Turkiye Klinikleri J Hem Onc-Special Topics 2012;5(4):87-93. 2- Blank, U., Karlsson, G., Karlsson, S., Dc, W. and Blank, U. (2011) Signaling pathways governing stem-cell fate Review article Signaling pathways governing stem-cell fate. 111, 492–503. 3- Zhu, J. and Emerson, S.G. (2002) Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene, 21, 3295–3313. 4- Passegué, E., Jamieson, C.H.M., Ailles, L.E. and Weissman, I.L. (2003) Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proceedings of the National Academy of Sciences of the United States of America, 100 Suppl , 11842–11849. 5- Kufe, Donald W., Pollock, Raphael E., Weichselbaum, Ralph R., Bast, Robert C., Jr.,Gansler, Ted S., Holland, James F. (2003). Frei III Cancer Medicine. Sixth Edition. Hamilton (Canada), BC Decker Inc (e-kitap). 6- Rosmarin, G. A., Yang, Z., Resendes, K. K. (2005). Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation, and leukemogenesis.Exp Hematol, 33, 131-143. 7- Finn, W. G, Peterson, L. C. (2004). Hematopathology in oncology, First Edition, New York,Boston, Cluwer Academic, 13-44. 8- Arceci, R. J., Hann, I. M., Smith, O. P. (2006). Pediatric Hematology 3th ed Malden,Massachusetts Blackwell. 450-81. 9- Poplack, D. G., Margolin, J. F. (1997). Management of common cancers of childhood. In: Poplack, D. G. editors. Principles and Practice of Pediatric Oncology I.Philedelphia: Saunders,:409-504. 10- Franks, L. M., Teich, N. M. (2001.) Introduction to the Cellular and Molecular Biology of Cancer. 3rd ed. New York: Oxford University Pres, Inc. 11- Inoue, K., Sugiyama, H., Ogawa, H., Nakagowa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Kyo, T., Dohy, H., Nakauchi, H., Ishidata, T., Akiyama, T., Kishimoto, T. (1994). WT1 as a new prognostic factor and a new marker for the detection of minimal reidual disease in acute leukemia. Blood. 84,30-71. 12- Neubauer, A., Dodge, R. K., George, S. L., Davey, F. R, Silver, R. T., Schiffer, C. A. (1994). Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 83,1603–1611. 13- Rozman C, Montserrat E. (1995). Currentconcepts: chronic lymphocytic leukemia, N Engl J Med,333, 1052-1057. 14- Yohe, S. (2015) Molecular Genetic Markers in Acute Myeloid Leukemia. Journal of Clinical Medicine, 4, 460–478. http://www.mdpi.com/2077-0383/4/3/460/. 15- Gönül OĞURa, Hatice MUTLU ALBAYRAK . Molecular Genetic Markers of Acute Myeloblastic Leukemia. Turkiye Klinikleri J Med Genet-Special Topics 2016;1(1):125-32 16- Chiaretti, S., Gianfelici, V., Ceglie, G. and Foà, R. (2014) Genomic Characterization of Acute Leukemias. Medical Principles and Practice, 23, 487–506. 17- Heim S, Mitelman F: Cancer cytogenetics. 2nd Ed. Willey Liss. Inc. New York 1995. 18- de Ravel, T.J.L., Devriendt, K., Fryns, J.-P. and Vermeesch, J.R. (2007) What’s new in karyotyping? The move towards array comparative genomic hybridisation (CGH). European journal of pediatrics, 166, 637–43. 19- Oostlander, A.E., Meijer, G.A. and Ylstra, B. (2004) Microarray-based comparative genomic hybridization and its applications in human genetics. Clinical genetics, 66, 488–495. 20- Lin, P. and Falini, B. (2015) Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations. American Journal of Clinical Pathology, 144, 19–28. 21- Raimondi SC. Cytogenetics of acute leukemias. In Pui CH Ed. Childhood leukemias, 2nd Eds. Cambridge University Press, Cambridge, UK. 22- Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008;86(6):480-7. 23- Giardine B, Borg J, Viennas E, Pavlidis C, Moradkhani K, Joly P, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic acids research. 2014;42(Database issue):D1063-9. 24-Synodinos JT. Harteveld HC. Preconception carrier screening and prenatal diagnosis in thalassemia and hemoglobinopathies: challenges and future perspectives. Expert Review of Molecular Diagnostics.2017; 17(3): 281-291. 25- Clark BE. Theın SL. Molecular diagnosis of haemoglobin disorders. Clin. Lab. Haem. 2004, 26, 159–176. 26- Ryan K. Bain BJ. Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br. J. Haematol. 2010; 149(1), 35–49. 27- Labbe RF. Vreman HJ. Stevenson DK. Zinc protoporphyrin: a metabolite with a mission. Clin. Chem. 1999; 45(12), 2060–2072
Year 2020,
Volume: 9 , 18 - 22, 29.06.2020
Abstract
Leukemia is a malignant disease originating from lymphopoietic or hematopoietic stem cells of bone marrow. Leukemias are classified as acute or chronic, based on the spread and development characteristics of the tumor. Leukemias exhibit phenotypic and genotypic heterogeneity according to their classification. Therefore, hematology is one of the sciences that most frequently use molecular biology tests. Although the classification and risk assessment are mainly based on cytogenetic analysis, molecular tests play a complementary role. The most commonly used tests include conventional karyotyping, fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR)-based single nucleotide polymorphism analyses (RFLP, ARMS etc.), comparative genomic hybridization (CGH), and sequence analysis methods. Molecular biology tests have become essential for the final diagnosis of malignant diseases, as well as determining the prognosis and even selection of treatment methods. Although cytogenetic and molecular indicators play a key role in determining the risk status of patients, there are also other prognostic indicators in long-term remission. The treatment response can also be evaluated by carrying out morphological, cytogenetic and molecular biology tests (MBT) on bone marrow samples collected at various times throughout the treatment period. In practice, MBTs can be used in the diagnosis and follow-up of benign hematologic disorders (hemoglobinopathies etc.) as well as malignant diseases. MBTs are also frequently used in the diagnosis of congenital or acquired hemolytic anemias, hemophilia, thrombophilia and platelet disorders. Therefore, it is possible to say that the genetic parameters obtained using different MBTs are of utmost importance in the diagnosis, treatment and follow-up period of prevalent malignant or benign hematologic diseases.
Keywords
References
- 1- İlknur KOZANOĞLU, Yusuf BARAN. The Use of Molecular Diagnostic Methods in Hematology Laboratory. Turkiye Klinikleri J Hem Onc-Special Topics 2012;5(4):87-93. 2- Blank, U., Karlsson, G., Karlsson, S., Dc, W. and Blank, U. (2011) Signaling pathways governing stem-cell fate Review article Signaling pathways governing stem-cell fate. 111, 492–503. 3- Zhu, J. and Emerson, S.G. (2002) Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene, 21, 3295–3313. 4- Passegué, E., Jamieson, C.H.M., Ailles, L.E. and Weissman, I.L. (2003) Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proceedings of the National Academy of Sciences of the United States of America, 100 Suppl , 11842–11849. 5- Kufe, Donald W., Pollock, Raphael E., Weichselbaum, Ralph R., Bast, Robert C., Jr.,Gansler, Ted S., Holland, James F. (2003). Frei III Cancer Medicine. Sixth Edition. Hamilton (Canada), BC Decker Inc (e-kitap). 6- Rosmarin, G. A., Yang, Z., Resendes, K. K. (2005). Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation, and leukemogenesis.Exp Hematol, 33, 131-143. 7- Finn, W. G, Peterson, L. C. (2004). Hematopathology in oncology, First Edition, New York,Boston, Cluwer Academic, 13-44. 8- Arceci, R. J., Hann, I. M., Smith, O. P. (2006). Pediatric Hematology 3th ed Malden,Massachusetts Blackwell. 450-81. 9- Poplack, D. G., Margolin, J. F. (1997). Management of common cancers of childhood. In: Poplack, D. G. editors. Principles and Practice of Pediatric Oncology I.Philedelphia: Saunders,:409-504. 10- Franks, L. M., Teich, N. M. (2001.) Introduction to the Cellular and Molecular Biology of Cancer. 3rd ed. New York: Oxford University Pres, Inc. 11- Inoue, K., Sugiyama, H., Ogawa, H., Nakagowa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Kyo, T., Dohy, H., Nakauchi, H., Ishidata, T., Akiyama, T., Kishimoto, T. (1994). WT1 as a new prognostic factor and a new marker for the detection of minimal reidual disease in acute leukemia. Blood. 84,30-71. 12- Neubauer, A., Dodge, R. K., George, S. L., Davey, F. R, Silver, R. T., Schiffer, C. A. (1994). Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 83,1603–1611. 13- Rozman C, Montserrat E. (1995). Currentconcepts: chronic lymphocytic leukemia, N Engl J Med,333, 1052-1057. 14- Yohe, S. (2015) Molecular Genetic Markers in Acute Myeloid Leukemia. Journal of Clinical Medicine, 4, 460–478. http://www.mdpi.com/2077-0383/4/3/460/. 15- Gönül OĞURa, Hatice MUTLU ALBAYRAK . Molecular Genetic Markers of Acute Myeloblastic Leukemia. Turkiye Klinikleri J Med Genet-Special Topics 2016;1(1):125-32 16- Chiaretti, S., Gianfelici, V., Ceglie, G. and Foà, R. (2014) Genomic Characterization of Acute Leukemias. Medical Principles and Practice, 23, 487–506. 17- Heim S, Mitelman F: Cancer cytogenetics. 2nd Ed. Willey Liss. Inc. New York 1995. 18- de Ravel, T.J.L., Devriendt, K., Fryns, J.-P. and Vermeesch, J.R. (2007) What’s new in karyotyping? The move towards array comparative genomic hybridisation (CGH). European journal of pediatrics, 166, 637–43. 19- Oostlander, A.E., Meijer, G.A. and Ylstra, B. (2004) Microarray-based comparative genomic hybridization and its applications in human genetics. Clinical genetics, 66, 488–495. 20- Lin, P. and Falini, B. (2015) Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations. American Journal of Clinical Pathology, 144, 19–28. 21- Raimondi SC. Cytogenetics of acute leukemias. In Pui CH Ed. Childhood leukemias, 2nd Eds. Cambridge University Press, Cambridge, UK. 22- Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008;86(6):480-7. 23- Giardine B, Borg J, Viennas E, Pavlidis C, Moradkhani K, Joly P, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic acids research. 2014;42(Database issue):D1063-9. 24-Synodinos JT. Harteveld HC. Preconception carrier screening and prenatal diagnosis in thalassemia and hemoglobinopathies: challenges and future perspectives. Expert Review of Molecular Diagnostics.2017; 17(3): 281-291. 25- Clark BE. Theın SL. Molecular diagnosis of haemoglobin disorders. Clin. Lab. Haem. 2004, 26, 159–176. 26- Ryan K. Bain BJ. Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br. J. Haematol. 2010; 149(1), 35–49. 27- Labbe RF. Vreman HJ. Stevenson DK. Zinc protoporphyrin: a metabolite with a mission. Clin. Chem. 1999; 45(12), 2060–2072
There are 1 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Engineering |
| Journal Section | Articles |
| Authors | |
| Publication Date | June 29, 2020 |
| Published in Issue | Year 2020Volume: 9 |
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.